The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
Sign in to access this content
Sign InIn a move reflecting the accelerating pace of strategic partnerships in the biotech sector, Innovent Biologics has entered into an exclusive license agreement with Spero Therapeutics to develop and commercialize the SP001 antibody globally, excluding Greater China. Under the terms, Innovent will receive an upfront payment and is eligible for development, regulatory, and commercial milestones totaling approximately $1.1 billion. Spero plans to initiate a Phase 2 study for patients with IgG4-related disease (IgG4-RD) in the second quarter of 2027.
This deal comes amid rising demand for innovative antibodies, as SP001 (also known as IBI355) represents a third-generation anti-CD40L therapy. Compared to similar sector moves, such as Sanofi's $2.9 billion acquisition of Provention Bio in 2023 to bolster its immunology pipeline, this agreement serves as a significant financial catalyst for Innovent. Per market data, successful Phase 2 trial initiations are critical valuation drivers for mid-cap biotech firms like Spero.
Regarding market performance, 1801.HK stood at 89.1 HKD, while SPRO closed at $2.18 (close July 13, 2026). Investors are closely monitoring regulatory updates regarding the 2027 Phase 2 study protocol, as long-term growth prospects remain tied to Spero's ability to fund clinical research and achieve the specified commercial milestones.